Abstract
ANTIPSYCHOTIC drugs, or neuroleptics, are thought to act by blocking dopamine receptors in the nervous system1–4. Recent direct evidence, based on stereospecific binding assays, supports this hypothesis of antipsychotic drug action5–9. As only a few antipsychotic drugs had been tested for their effects on the binding of haloperidol5–8, the question remained whether all antipsychotic drugs, regardless of chemical structure, would block the stereospecific binding of haloperidol. We report here that all clinically effective antipsychotic drugs (tested so far) block the stereo-specific binding of 3H-haloperidol at concentrations which correlate directly with the clinical potencies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Van Rossum, J. M., Arch. int. Pharmacodyn., 160, 492–494 (1966).
Iversen, L. L., Science, 188, 1084–1089 (1975).
Horn, A. S., Post, M. L., and Kennard, O., J. Pharm. Pharmac., 27, 553–563 (1975).
Matthysse, S., Fedn Proc., 32, 200–204 (1973).
Seeman, P., Wong, M., and Lee, T., Fedn Proc., 33, 246 (1974).
Seeman, P., Wong, M., and Tedesco, J., Proc. Neurosci. Soc., 5, 405 (1975).
Seeman, P., Chau-Wong, M., Tedesco, J., and Wong, K., Proc. natn. Acad. Sci. U.S.A., 72, 4376–4380 (1975).
Creese, I., Burt, D. R., and Snyder, S. H., Life Sci., 17, 993–1002 (1975).
Burt, D. R., Enna, S., Creese, I., and Snyder, S. H., Proc. natn. Acad. Sci. U.S.A., 72, 4655–4659 (1975).
Seeman, P., Pharmac. Rev., 24, 583–655 (1972).
Seeman, P., Staiman, A., and Chau-Wong, M., J. Pharmac. exp. Ther., 190, 123–130 (1974).
Seeman, P., and Lee, T., Science, 188, 1217–1219 (1975).
Seeman, P., in Antipsychotic Drugs, Pharmacodynamics and Pharmacokinetics (edit. by Sedvall, G.) (Pergamon, Oxford, in the press).
Forsman, A., Mårtensson, E., Nyberg, G., and Ohman, R., Naunyn–Schmiedeberg's Arch. Pharmac., 286, 113–124 (1974).
Sakalis, G., Curry, S. H., Mould, G. P., and Lader, M. H., Clin. Pharmac. Ther., 13, 931–946 (1972).
Cooper, S. F., Albert, J.-M., Hillel, J., and Caille, G., Curr. Ther. Res., 15, 73–77 (1973).
Pecknold, J. C., Ban, T. A., Lehmann, H. E., and Climan, M., Int. J. clin. Pharmac., 11, 299–303 (1975).
Simpson, G. M., and Varga, V., Curr. Ther. Res., 16, 477–482 (1974).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
SEEMAN, P., LEE, T., CHAU-WONG, M. et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717–719 (1976). https://doi.org/10.1038/261717a0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/261717a0
This article is cited by
-
Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia
Schizophrenia (2024)
-
Towards a Unified Account of Aberrant Salience in Psychosis: Proximate and Evolutionary Mechanisms
Evolutionary Psychological Science (2024)
-
Chronic treatment with D2-antagonist haloperidol leads to inhibitory/excitatory imbalance in striatal D1-neurons
Translational Psychiatry (2023)
-
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia
Neuropsychopharmacology (2023)
-
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
CNS Drugs (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
